Literature DB >> 26858355

Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.

Stefano Sacchi1, Raffaella Marcheselli2, Alessia Bari2, Gabriele Buda3, Anna Lia Molinari4, Luca Baldini5, Daniele Vallisa6, Marina Cesaretti2, Pellegrino Musto7, Sonia Ronconi8, Giorgina Specchia9, Franco Silvestris10, Luciano Guardigni11, Angela Ferrari, Annalisa Chiapella12, Angelo Michele Carella13, Armando Santoro14, Francesco Di Raimondo15, Luigi Marcheselli2, Samantha Pozzi2.   

Abstract

Entities:  

Keywords:  efficacy; indolent; lenalidomide; non-follicular lymphoma; recurrent; rituximab; safety

Mesh：

Substances：

Year:  2016        PMID： 26858355      PMCID： PMC5004354          DOI： 10.3324/haematol.2015.139329

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients.

Authors:  Stefano Sacchi; Samantha Pozzi; Luigi Marcheselli; Alessia Bari; Stefano Luminari; Francesco Angrilli; Francesco Merli; Daniele Vallisa; Luca Baldini; Maura Brugiatelli
Journal:  Cancer       Date:  2007-05-15       Impact factor: 6.860

3.  Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.

Authors:  Liang Zhang; Zhengzi Qian; Zhen Cai; Luhong Sun; Huaqing Wang; J Blake Bartlett; Qing Yi; Michael Wang
Journal:  Am J Hematol       Date:  2009-09       Impact factor: 10.047

4.  Towards a chemotherapy-free approach in indolent lymphoma.

Authors:  Christian Buske
Journal:  Lancet Oncol       Date:  2014-10-15       Impact factor: 41.316

5.  Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.

Authors:  Joseph M Tuscano; Mrinal Dutia; Karen Chee; Ann Brunson; Christine Reed-Pease; Mehrdad Abedi; Jeanna Welborn; Robert T O'Donnell
Journal:  Br J Haematol       Date:  2014-03-07       Impact factor: 6.998

6.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.

Authors:  P F Thall; R M Simon; E H Estey
Journal:  Stat Med       Date:  1995-02-28       Impact factor: 2.373

7.  Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.

Authors:  Nishitha Reddy; Francisco J Hernandez-Ilizaliturri; George Deeb; Mark Roth; Mary Vaughn; Joy Knight; Paul Wallace; Myron S Czuczman
Journal:  Br J Haematol       Date:  2007-11-09       Impact factor: 6.998

8.  Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).

Authors:  John P Leonard; Sin-Ho Jung; Jeffrey Johnson; Brandelyn N Pitcher; Nancy L Bartlett; Kristie A Blum; Myron Czuczman; Jeffrey K Giguere; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

9.  Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

Authors:  Ian W Flinn; Richard van der Jagt; Brad S Kahl; Peter Wood; Tim E Hawkins; David Macdonald; Mark Hertzberg; Yiu-Lam Kwan; David Simpson; Michael Craig; Kathryn Kolibaba; Samar Issa; Regina Clementi; Doreen M Hallman; Mihaela Munteanu; Ling Chen; John M Burke
Journal:  Blood       Date:  2014-03-03       Impact factor: 22.113

10.  Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.

Authors:  Thomas E Witzig; Peter H Wiernik; Timothy Moore; Craig Reeder; Craig Cole; Glen Justice; Henry Kaplan; Michael Voralia; Dennis Pietronigro; Kenichi Takeshita; Annette Ervin-Haynes; Jerome B Zeldis; Julie M Vose
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544
View more
  4 in total

Review 1.  Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority.

Authors:  Ying Yuan; J Jack Lee; Susan G Hilsenbeck
Journal:  JCO Precis Oncol       Date:  2019-10-24

2.  Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial.

Authors:  Franck Morschhauser; Nilanjan Ghosh; Izidore S Lossos; M Lia Palomba; Amitkumar Mehta; Olivier Casasnovas; Don Stevens; Sudhakar Katakam; Andrea Knapp; Tina Nielsen; Ron McCord; Gilles Salles
Journal:  Blood Cancer J       Date:  2021-08-20       Impact factor: 11.037

3.  Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.

Authors:  Hsiling Chiu; Preeti Trisal; Chad Bjorklund; Soraya Carrancio; Estela G Toraño; Carla Guarinos; Despoina Papazoglou; Patrick R Hagner; Asma Beldi-Ferchiou; Karin Tarte; Marie-Hélène Delfau-Larue; Franck Morschhauser; Alan G Ramsay; Anita K Gandhi
Journal:  Br J Haematol       Date:  2019-02-14       Impact factor: 6.998

4.  Sample Size Requirements for Calibrated Approximate Credible Intervals for Proportions in Clinical Trials.

Authors:  Fulvio De Santis; Stefania Gubbiotti
Journal:  Int J Environ Res Public Health       Date:  2021-01-12       Impact factor: 3.390
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.